Osman Essam Eldin A, Toogood Peter L, Neamati Nouri
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
ACS Infect Dis. 2020 Jul 10;6(7):1548-1552. doi: 10.1021/acsinfecdis.0c00224. Epub 2020 May 10.
Novel beta-coronavirus SARS-CoV-2 is the pathogenic agent responsible for coronavirus disease-2019 (COVID-19), a globally pandemic infectious disease. Due to its high virulence and the absence of immunity among the general population, SARS-CoV-2 has quickly spread to all countries. This pandemic highlights the urgent unmet need to expand and focus our research tools on what are considered "neglected infectious diseases" and to prepare for future inevitable pandemics. This global emergency has generated unprecedented momentum and scientific efforts around the globe unifying scientists from academia, government and the pharmaceutical industry to accelerate the discovery of vaccines and treatments. Herein, we shed light on the virus structure and life cycle and the potential therapeutic targets in SARS-CoV-2 and briefly refer to both active and passive immunization modalities, drug repurposing focused on speed to market, and novel agents against specific viral targets as therapeutic interventions for COVID-19.
新型β冠状病毒严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是导致2019冠状病毒病（COVID-19）的病原体，这是一种全球大流行的传染病。由于其高毒力以及普通人群中缺乏免疫力，SARS-CoV-2已迅速传播到所有国家。这场大流行凸显了迫切需要扩大并将我们的研究工具集中于被视为“被忽视的传染病”，并为未来不可避免的大流行做好准备。这一全球紧急情况在全球范围内产生了前所未有的势头和科学努力，使来自学术界、政府和制药行业的科学家团结起来，以加速疫苗和治疗方法的发现。在此，我们阐明了该病毒的结构和生命周期以及SARS-CoV-2中的潜在治疗靶点，并简要提及主动和被动免疫方式、以加快上市速度为重点的药物重新利用，以及针对特定病毒靶点的新型药物作为COVID-19的治疗干预措施。
